{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:16:54Z","timestamp":1792858614884,"version":"4.5.0"},"reference-count":87,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,10,31]]},"DOI":"10.5582\/bst.2025.01292","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T22:06:48Z","timestamp":1761689208000},"page":"495-510","source":"Crossref","is-referenced-by-count":4,"title":["Chinese expert consensus on the combined use of antiviral drugs for influenza"],"prefix":"10.5582","volume":"19","author":[{"given":"Jing","family":"Yuan","sequence":"first","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Zou","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Weng","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Bai","sequence":"additional","affiliation":[{"name":"Foshan First People&apos;s Hospital, Foshan Hospital Affiliated to Southern University of Science and Technology, Foshan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center, Fudan University, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Chong","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Deng","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Fu","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyun","family":"Fu","sequence":"additional","affiliation":[{"name":"Shenzhen People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Zhongshan Second People&apos;s Hospital, Zhongshan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojiong","family":"Gong","sequence":"additional","affiliation":[{"name":"Renmin Hospital of Wuhan University, Wuhan, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Huang","sequence":"additional","affiliation":[{"name":"Shenzhen Bao&apos;an People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"Shenzhen Second People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Huang","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianning","family":"Jiang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongmeng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital of Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingliang","family":"Lin","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[{"name":"The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"Hainan General Hospital, Haikou, Hainan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[{"name":"Nanfang hospital, Southern Medical University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Qi","sequence":"additional","affiliation":[{"name":"The Ninth People&apos;s Hospital of Dongguan, Dongguan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Qu","sequence":"additional","affiliation":[{"name":"Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shi","sequence":"additional","affiliation":[{"name":"Shenzhen People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[{"name":"Hainan Public Health Clinical Center, Haikou, Hainan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhongshan Second People&apos;s Hospital, Zhongshan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xiao","sequence":"additional","affiliation":[{"name":"The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[{"name":"The Ninth People&apos;s Hospital of Dongguan, Dongguan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijin","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Ninth People&apos;s Hospital of Dongguan, Dongguan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanlin","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Fifth People&apos;s Hospital of Ganzhou, Ganzhou, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbin","family":"Chen","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Medical Research Center for Infectious Diseases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to Influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019; 7:69-89.","DOI":"10.1016\/S2213-2600(18)30496-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Li L, Liu Y, Wu P, <i>et al.<\/i> Influenza-associated excess respiratory mortality in China, 2010-15: a population-based study. Lancet Public Health. 2019; 4:e473-e481.","DOI":"10.1016\/S2468-2667(19)30163-X"},{"key":"3","unstructured":"3. World Health Organization. Global Influenza strategy 2019-2030.[2019-03-11] <i>https:\/\/iris.who.int\/handle\/10665\/311184<\/i>. (accessed September 10, 2025)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. \u015awierczy\u0144ska M, Mirowska-Guzel DM, Pindelska E. Antiviral Drugs in Influenza. Int J Environ Res Public Health. 2022; 19:3018.","DOI":"10.3390\/ijerph19053018"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wang Y, Guo Q, Yan Z, <i>et al.<\/i> Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. J Infect Dis. 2018; 217:1708-1717.","DOI":"10.1093\/infdis\/jiy115"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019; 23:214.","DOI":"10.1186\/s13054-019-2491-9"},{"key":"7","unstructured":"7. Zou QD, Bao JQ, Zheng SF, Chen Y. Research on the Mechanisms of Severe Influenza and Advances in Treatment. Journal of Medical Research. 2019; 48:5-8. (in Chinese)"},{"key":"8","unstructured":"8. Song RR, Xu JY, Liu HY, Xu YT, Chang K, Cao B. Advances in Antiviral Treatment for Influenza. Chinese Medical Journal. 2023; 103:293-299. (in Chinese)"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Han J, Perez J, Schafer A, Cheng H, Peet N, Rong L, Manicassamy B. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Curr Med Chem. 2018; 25:5115-5127.","DOI":"10.2174\/0929867324666170920165926"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cao B, Hayden FG. Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. Lancet. 2020; 396:1310-1311.","DOI":"10.1016\/S0140-6736(20)32078-X"},{"key":"11","unstructured":"11. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence. [2010-01-07] <i>https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence<\/i> (accessed September 10, 2025)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bonomini A, Mercorelli B, Loregian A. Antiviral strategies against Influenza virus: an update on approved and innovative therapeutic approaches. Cell Mol Life Sci. 2025; 82:75.","DOI":"10.1007\/s00018-025-05611-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Batool S, Chokkakula S, Song MS. Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy. Microorganisms. 2023; 11:183.","DOI":"10.3390\/microorganisms11010183"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Xu J, Luo Q, Huang Y, Li J, Ye W, Yan R, Zhou X, He Z, Liu G, Zhu Q. Influenza neuraminidase mutations and resistance to neuraminidase inhibitors. Emerg Microbes Infect. 2024; 13:2429627.","DOI":"10.1080\/22221751.2024.2429627"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tramontana AR, George B, Hurt AC, <i>et al.<\/i> Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010; 16:1068-1075.","DOI":"10.3201\/eid1607.091691"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lee N, Hurt AC. Neuraminidase inhibitor resistance in Influenza: a clinical perspective. Curr Opin Infect Dis. 2018; 31:520-526.","DOI":"10.1097\/QCO.0000000000000498"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wang X, Kim KW, Walker G, Stelzer-Braid S, Scotch M, Rawlinson WD. Genome characterization of Influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high-throughput whole genome sequencing. Influenza Other Respir Viruses. 2024; 18:e13252.","DOI":"10.1111\/irv.13252"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM. Efficient transmission of pandemic H1N1 Influenza viruses with high-level oseltamivir resistance. J Virol. 2012; 86:5386-5389.","DOI":"10.1128\/JVI.00151-12"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hickerson BT, Petrovskaya SN, Dickensheets H, Donnelly RP, Ince WL, Ilyushina NA. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility. J Virol. 2023; 97:e0015423.","DOI":"10.1128\/jvi.00154-23"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Xie Z, Yang J, Jiao W, Li X, Iqbal M, Liao M, Dai M. Clade 2.3.4.4b highly pathogenic avian Influenza H5N1 viruses: knowns, unknowns, and challenges. J Virol. 2025; 99:e0042425.","DOI":"10.1128\/jvi.00424-25"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pulit-Penaloza JA, Brock N, Belser JA, Sun X, Pappas C, Kieran TJ, Basu Thakur P, Zeng H, Cui D, Frederick J, Fasce R, Tumpey TM, Maines TR. Highly pathogenic avian Influenza A(H5N1) virus of clade 2.3.4.4b isolated from a human case in Chile causes fatal disease and transmits between co-housed ferrets. Emerg Microbes Infect. 2024; 13:2332667.","DOI":"10.1080\/22221751.2024.2332667"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mostafa A, Naguib MM, Nogales A, Barre RS, Stewart JP, Garc\u00eda-Sastre A, Martinez-Sobrido L. Avian Influenza A (H5N1) virus in dairy cattle: origin, evolution, and cross-species transmission. mBio. 2024; 15:e0254224.","DOI":"10.1128\/mbio.02542-24"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Azeem RM, Yang YS, Sehrish S, Shi CW, Yang GL, Kumar ST, Yang WT, Wang CF. Emerging threats of H5N1 clade 2.3.4.4b: cross-species transmission, pathogenesis, and pandemic risk. Front Cell Infect Microbiol. 2025; 15:1625665.","DOI":"10.3389\/fcimb.2025.1625665"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Abed Y, Boivin G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open Forum Infect Dis. 2017; 4:ofx105.","DOI":"10.1093\/ofid\/ofx105"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Aw DZH, Zhang DX, Vignuzzi M. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. NPJ Antimicrob Resist. 2025; 3:54.","DOI":"10.1038\/s44259-025-00125-z"},{"key":"26","unstructured":"26. World Health Organization. Clinical practice guidelines for Influenza. [2024-09-12] <i>https:\/\/iris.who.int\/handle\/10665\/378872<\/i> (accessed September 10, 2025)."},{"key":"27","unstructured":"27. National Health Commission. Diagnosis and Treatment Protocol for Influenza (2020 Edition). Infectious Disease Information. 2020; 33:385-390. (in Chinese)"},{"key":"28","unstructured":"28. National Health Commission. Diagnosis and Treatment Protocol for Influenza (2025 Edition). Chinese Journal of Viral Diseases. 2025; 15:101-106. (in Chinese)"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Salvatore M, Laplante JM, Soave R, Orfali N, Plate M, van Besien K, St George K. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020; 22:e13336.","DOI":"10.1111\/tid.13336"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Guan W, Qu R, Shen L, <i>et al.<\/i> Baloxavir marboxil use for critical human infection of avian Influenza A H5N6 virus. Med. 2024; 5:32-41.e5.","DOI":"10.1016\/j.medj.2023.11.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Pizzorno A, Abed Y, Rh\u00e9aume C, Boivin G. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with Influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res. 2014; 105:54-58.","DOI":"10.1016\/j.antiviral.2014.02.017"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Pires de Mello CP, Drusano GL, Adams JR, Shudt M, Kulawy R, Brown AN. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 Influenza A viruses in the hollow fiber infection model (HFIM) system. Eur J Pharm Sci. 2018; 111:443-449.","DOI":"10.1016\/j.ejps.2017.10.027"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentr\u00e9 F, Leport C. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal Influenza: a randomized placebo-controlled trial. PLoS Med. 2010; 7:e1000362.","DOI":"10.1371\/journal.pmed.1000362"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Zhang Y, Gao H, Liang W, Tang L, Yang Y, Wu X, Yu L, Chen P, Zheng S, Ou H, Li L. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infect Dis. 2016; 16:76.","DOI":"10.1186\/s12879-016-1383-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Petersen E, Keld DB, Ellermann-Eriksen S, Gubbels S, Ilkj\u00e6r S, Jensen-Fangel S, Lindskov C. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic Influenza A (H1N1)v. Scand J Infect Dis. 2011; 43:495-503.","DOI":"10.3109\/00365548.2011.556144"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Guo X, Zhao L, Li W, Cao R, Zhong W. The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses <i>In Vitro<\/i>. Viruses. 2024; 16:1467.","DOI":"10.3390\/v16091467"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Koszalka P, George A, Dhanasekaran V, Hurt AC, Subbarao K. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA\/I38T or PA\/E23K Substitutions in the Ferret Model. mBio. 2022; 13:e0105622.","DOI":"10.1128\/mbio.01056-22"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Angelidakis G, Khawaja F, Mulanovich VE, Dailey-Garnes N, Ariza-Heredia E, Chemaly RF. Combination of baloxavir and oseltamivir for treatment of severe Influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population. Microbes Infect. 2022; 24:104895.","DOI":"10.1016\/j.micinf.2021.104895"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Euzen V, Xhaard A, Berreira-Ibraim S, Deville L, Quentin A, De Lima Prata PH, Gournay V, Prot M, Rahou Y, Barbet M, Mercier-Delarue S, Peffault De La Tour R, Simon-Loriere E, Legoff J. Zanamivir and baloxavir combination to cure persistent Influenza and coronavirus infections after hematopoietic stem cell transplant. Int J Antimicrob Agents. 2024; 64:107281.","DOI":"10.1016\/j.ijantimicag.2024.107281"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020; 221:1688-1698.","DOI":"10.1093\/infdis\/jiz656"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. O&apos;Neil B, Ison MG, Hallouin-Bernard MC, Nilsson AC, Torres A, Wilburn JM, van Duijnhoven W, Van Dromme I, Anderson D, Deleu S, Kosoglou T, Vingerhoets J, Rossenu S, Leopold L. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study. J Infect Dis. 2022; 226:109-118.","DOI":"10.1093\/infdis\/jiaa376"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, Kosoglou T, Vingerhoets J, Leopold L. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. J Infect Dis. 2019; 219:1026-1034.","DOI":"10.1093\/infdis\/jiy547"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Paules CI, Lakdawala S, McAuliffe JM, Paskel M, Vogel L, Kallewaard NL, Zhu Q, Subbarao K. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses. J Infect Dis. 2017; 216:356-365.","DOI":"10.1093\/infdis\/jix292"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Ali SO, Takas T, Nyborg A, Shoemaker K, Kallewaard NL, Chiong R, Dubovsky F, Mallory RM. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza. Antimicrob Agents Chemother. 2018; 62:e00694-18.","DOI":"10.1128\/AAC.00694-18"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Yi KS, Choi JA, Kim P, <i>et al.<\/i> Broader neutralization of CT-P27 against Influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020; 15:e0236172.","DOI":"10.1371\/journal.pone.0236172"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kiso M, Yamayoshi S, Kawaoka Y. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates Influenza virus from nude mice. Commun Biol. 2020; 3:219.","DOI":"10.1038\/s42003-020-0952-y"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Gaisina I, Li P, Du R, Cui Q, Dong M, Zhang C, Manicassamy B, Caffrey M, Moore T, Cooper L, Rong L. An orally active entry inhibitor of Influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil. Sci Adv. 2024; 10:eadk9004.","DOI":"10.1126\/sciadv.adk9004"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Koszalka P, Subbarao K, Baz M. Preclinical and clinical developments for combination treatment of Influenza. PLoS Pathog. 2022; 18:e1010481.","DOI":"10.1371\/journal.ppat.1010481"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Hung IFN, To KKW, Chan JFW, <i>et al.<\/i> Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb\/III Trial. Chest. 2017; 151:1069-1080.","DOI":"10.1016\/j.chest.2016.11.012"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Lee CW, Tai YL, Huang LM, Chi H, Huang FY, Chiu NC, Huang CY, Tu YH, Wang JY, Huang DT. Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric Influenza patients. J Microbiol Immunol Infect. 2021; 54:876-884.","DOI":"10.1016\/j.jmii.2020.08.017"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Long JS, Mistry B, Haslam SM, Barclay WS. Host and viral determinants of Influenza A virus species specificity. Nat Rev Microbiol. 2019; 17:67-81.","DOI":"10.1038\/s41579-018-0115-z"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Shin WJ, Seong BL. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of Influenza virus strains. Expert Opin Drug Discov. 2019; 14:153-168.","DOI":"10.1080\/17460441.2019.1560261"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Lee D, Jo H, Jang Y, Bae S, Agura T, Kang D, Kang M, Kim Y, Cho NH, Kim Y, Kang JS. Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection <i>In Vitro<\/i> and <i>In Vivo<\/i>. Int J Mol Sci. 2022; 24:678.","DOI":"10.3390\/ijms24010678"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Mifsud EJ, Tilmanis D, Oh DY, Ming-Kay Tai C, Rossignol JF, Hurt AC. Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of Influenza a virus infection compared to oseltamivir monotherapy. Antiviral Res. 2020; 176:104751.","DOI":"10.1016\/j.antiviral.2020.104751"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Hamza H, Shehata MM, Mostafa A, Pleschka S, Planz O. Improved <i>in vitro<\/i> Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. Front Microbiol. 2021; 12:611958.","DOI":"10.3389\/fmicb.2021.611958"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Haasbach E, Hartmayer C, Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after Influenza A virus infection <i>in vitro<\/i>. Antiviral Res. 2013; 98:319-324.","DOI":"10.1016\/j.antiviral.2013.03.006"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Ashar HK, Pulavendran S, Rudd JM, Maram P, Achanta M, Chow VTK, Malayer JR, Snider TA, Teluguakula N. Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection. Am J Pathol. 2021; 191:669-685.","DOI":"10.1016\/j.ajpath.2020.12.013"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Washburn ML, Crosby R, Remlinger K, Wang F, Creech D. Therapeutically Attenuating Neutrophil Recruitment With a CXCR2 Antagonist in Combination With Oseltamivir Ameliorates Influenza-Induced Lung Injury and Disease. Open Forum Infect Dis. 2019; 6:ofz106.","DOI":"10.1093\/ofid\/ofz106"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. O&apos;Hanlon R, Leyva-Grado VH, Sourisseau M, Evans MJ, Shaw ML. An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir. ACS Infect Dis. 2019; 5:1779-1793.","DOI":"10.1021\/acsinfecdis.9b00230"},{"key":"60","unstructured":"60. Meetings of the WHO working group on surveillance of Influenza antiviral susceptibility \u2013 Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012; 87:369-374."},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Van Poelvoorde LAE, Saelens X, Thomas I, Roosens NH. Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza. Trends Biotechnol. 2020; 38:360-367.","DOI":"10.1016\/j.tibtech.2019.09.009"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Mu S, Zou X, Wang Y, Deng X, Cui D, Liu S, Cao B. The combined effect of oseltamivir and favipiravir on Influenza A virus evolution in patients hospitalized with severe Influenza. Antiviral Res. 2023; 216:105657.","DOI":"10.1016\/j.antiviral.2023.105657"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. <i>In vitro<\/i> and <i>in vivo<\/i> activities of anti-Influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46:977-981.","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 Influenza A viruses. Proc Natl Acad Sci U S A. 2010; 107:882-887.","DOI":"10.1073\/pnas.0909603107"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Smee DF, Barnard DL, Jones SM. Activities of JNJ63623872 and oseltamivir against Influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016; 136:45-50.","DOI":"10.1016\/j.antiviral.2016.10.009"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Clark MP, Ledeboer MW, Davies I, <i>et al.<\/i> Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of Influenza PB2. J Med Chem. 2014; 57:6668-6678.","DOI":"10.1021\/jm5007275"},{"key":"67","unstructured":"67. Janssen Research &amp; Development, LLC. A study to evaluate the efficacy and safety of pimodivir in combination with the standard-of-care treatment in adolescent, adult, and elderly non-hospitalized participants with Influenza a infection who are at risk of developing complications [2025-02-03] <i>https:\/\/clinicaltrials.gov\/ct2\/show\/results\/nct03381196?Cond=pimodivir&amp;draw=2&amp;rank=6&amp;view=results<\/i> (accessed September 15, 2025)."},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Park JH, Kim B, Antigua KJC, Jeong JH, Kim CI, Choi WS, Oh S, Kim CH, Kim EG, Choi YK, Baek YH, Song MS. Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in Influenza A virus PA gene in a mouse model. Antiviral Res. 2021; 193:105126.","DOI":"10.1016\/j.antiviral.2021.105126"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Bay P, Martin-Loeches I, Haudebourg AF, L\u00ea MP, Peytavin G, Rameix-Welti MA, Fourati S, de Prost N. How to manage antivirals in critically ill patients with Influenza? Clin Microbiol Infect. 2025; 31:1157-1165.","DOI":"10.1016\/j.cmi.2025.04.002"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Fukao K, Noshi T, Yamamoto A, Kitano M, Ando Y, Noda T, Baba K, Matsumoto K, Higuchi N, Ikeda M, Shishido T, Naito A. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of Influenza A virus infection. J Antimicrob Chemother. 2019; 74:654-662.","DOI":"10.1093\/jac\/dky462"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Yan M, Gu X, Wang Y, Cao B. Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial. Open Forum Infect Dis. 2025; 12:ofaf439.","DOI":"10.1093\/ofid\/ofaf439"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Mhamdi Z, Fausther-Bovendo H, Uyar O, Carbonneau J, Venable MC, Abed Y, Kobinger G, Boivin G, Baz M. Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A\/H3N2 Virus. Microorganisms. 2020; 8:1968.","DOI":"10.3390\/microorganisms8121968"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Meijer WJ, Kromdijk W, van den Broek MP, Haas PJ, Minnema MC, Boucher CA, de Lange DW, Wensing AM. Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir. Case Rep Infect Dis. 2015; e504975.","DOI":"10.1155\/2015\/504975"},{"key":"74","unstructured":"74. Consensus Expert Group on Antiviral Treatment for Adult Influenza. Expert Consensus on Antiviral Treatment for Influenza in Adults. Chinese Journal of Infectious Diseases. 2022; 40:641-655. (in Chinese)"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Uyeki TM, Bernstein HH, Bradley JS, <i>et al.<\/i> Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019; 68:e1-e47.","DOI":"10.1093\/cid\/ciy866"},{"key":"76","unstructured":"76. Pediatric Infectious Diseases Working Group IDS, Pediatric Committee, National Health Commission Capacity Building and Continuing Education Commission, Chinese Clinical Practice Guidelines Alliance Methodology Subcommittee. Practical Guidelines for Influenza Vaccination and Antiviral Drug Use in Children (2024 Edition). Chinese Medical Journal. 2024; 104:3705-3725. (in Chinese)"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Chen X, Ma Q, Zhao M, Yao Y, Zhang Q, Liu M, Yang Z, Deng W. Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase. Pharmaceuticals (Basel). 2023; 16:365.","DOI":"10.3390\/ph16030365"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Pang Y, Li H, Chen X, Cao Y, Jiang H, Huang J, Liu Y. A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects. Antimicrob Agents Chemother. 2025; 69:e0172924.","DOI":"10.1128\/aac.01729-24"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Jiang Y, Wen J, Sun J, Shu Y. Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission-Economic Evaluation Model. Pharmacoeconomics. 2024; 42:1111-1125.","DOI":"10.1007\/s40273-024-01412-9"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Nakagawa N, Ono R, Odanaka K, Ohara H, Kisara S, Ito K. A Pharmacoeconomic Study of Post-Exposure Prophylaxis Strategies for Influenza Virus Infections in Japan. Adv Ther. 2025; 42:772-787.","DOI":"10.1007\/s12325-024-02988-6"},{"key":"81","unstructured":"81. Pediatric Committee of the Chinese Medical Education Association, Respiratory Subspecialty Group of the Pediatrics Branch CMA, Pediatric Respiratory Working Committee of the Respiratory Physicians Branch CMDA, Pediatric Committee of the Chinese Research Hospital Association, Pediatric Committee of the China Non-public Medical Institutions Association, Pediatric Health and Drug Research Committee of the China Association of Traditional Chinese Medicine, Pediatric Drug Safety Branch of the China Medical News and Information Association, Pediatric Expert Committee of the China Primary Health Care Foundation, Global Pediatric Respiratory Alliance, Beijing Yao Dun Public Welfare Foundation. Guidelines for Diagnosis, Treatment, and Prevention of Influenza in Children (2024 Physician Edition). Chinese Journal of Practical Pediatrics. 2024; 39:881-895. (in Chinese)"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Hussain S, Meijer A, Govorkova EA, <i>et al.<\/i> Global update on the susceptibilities of Influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023. Antiviral Res. 2025; 241:106217.","DOI":"10.1016\/j.antiviral.2025.106217"},{"key":"83","unstructured":"83. China Centers for Disease Control and Prevention. China Influenza Surveillance Weekly Report 2025, Week 35, Issue 872. [2025-09-03] <i>https:\/\/www.chinacdc.cn\/jksj\/jksj04_14249\/202509\/t20250903_310160.html<\/i> (accessed September 15, 2025). (in Chinese)"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Wang S, Zhang Th, Hu M, <i>et al.<\/i> Deep mutational scanning of Influenza A virus neuraminidase facilitates the identification of drug resistance mutations <i>in vivo<\/i>. mSystems. 2023; 8:e0067023.","DOI":"10.1128\/msystems.00670-23"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Shah SAW, Palomar DP, Barr I, Poon LLM, Quadeer AA, McKay MR. Seasonal antigenic prediction of Influenza A H3N2 using machine learning. Nat Commun. 2024; 15:3833.","DOI":"10.1038\/s41467-024-47862-9"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Lou J, Liang W, Cao L, <i>et al.<\/i> Predictive evolutionary modelling for Influenza virus by site-based dynamics of mutations. Nat Commun. 2024; 15:2546.","DOI":"10.1038\/s41467-024-46918-0"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Yang B, Gostic KM, Adam DC, Zhang R, Einav T, Peng L, Wong SS, Tsang TK, Cummings DAT, Sullivan SG, Cobey S, Cowling BJ. Breadth of Influenza A antibody cross-reactivity varies by virus isolation interval and subtype. Nat Microbiol. 2025; 10:1711-1722.","DOI":"10.1038\/s41564-025-02033-4"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/5\/19_2025.01292\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:03:47Z","timestamp":1763179427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/5\/19_2025.01292\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01292","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"2025.01292"}}